Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
Get Alerts RPRX Hot Sheet
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 2.8%
Revenue Growth %: -1.8%
Join SI Premium – FREE
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021 at 9:40 a.m. ET.
The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on around 40 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772[email protected]
Source: RP Management, LLCSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vaxxinity Issues Shareholder Letter
- DMOS Revolutionizes Decentralized Computing Landscape with Groundbreaking Cloud Operating System
- Elevate Textiles Names Jeffrey P. Pritchett Chief Executive Officer and Director of the Board
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!